share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/12/07 06:10

Moomoo AI 已提取核心訊息

On December 5, 2024, Adial Pharmaceuticals entered into an Amended and Restated Employment Agreement with CEO Cary Claiborne. This agreement, effective immediately, extends Mr. Claiborne's tenure for three years, replacing the previous agreement from December 2021.Under the new terms, Mr. Claiborne's bonus target is increased to 50% of his base salary, contingent on meeting objectives set by the board. Additionally, he received stock options for 350,000 shares, vesting monthly over 36 months, under the 2017 Equity Incentive Plan.This strategic move aims to align leadership incentives with company goals, potentially enhancing shareholder value. The full agreement is available as Exhibit 10.1 in the company's latest SEC filing.
On December 5, 2024, Adial Pharmaceuticals entered into an Amended and Restated Employment Agreement with CEO Cary Claiborne. This agreement, effective immediately, extends Mr. Claiborne's tenure for three years, replacing the previous agreement from December 2021.Under the new terms, Mr. Claiborne's bonus target is increased to 50% of his base salary, contingent on meeting objectives set by the board. Additionally, he received stock options for 350,000 shares, vesting monthly over 36 months, under the 2017 Equity Incentive Plan.This strategic move aims to align leadership incentives with company goals, potentially enhancing shareholder value. The full agreement is available as Exhibit 10.1 in the company's latest SEC filing.
2024年12月5日,Adial Pharmicals與首席執行官卡里·克萊伯恩簽訂了經修訂和重述的僱傭協議。該協議立即生效,將克萊伯恩先生的任期延長三年,從2021年12月起取代先前的協議。根據新條款,克萊伯恩先生的獎金目標將提高到其基本工資的50%,前提是實現董事會設定的目標。此外,根據2017年股權激勵計劃,他獲得了35萬股股票的股票期權,在36個月內每月解鎖。這一戰略舉措旨在使領導層激勵措施與公司目標保持一致,從而有可能提高股東價值。完整協議載於該公司最新的美國證券交易委員會文件中的附錄10.1。
2024年12月5日,Adial Pharmicals與首席執行官卡里·克萊伯恩簽訂了經修訂和重述的僱傭協議。該協議立即生效,將克萊伯恩先生的任期延長三年,從2021年12月起取代先前的協議。根據新條款,克萊伯恩先生的獎金目標將提高到其基本工資的50%,前提是實現董事會設定的目標。此外,根據2017年股權激勵計劃,他獲得了35萬股股票的股票期權,在36個月內每月解鎖。這一戰略舉措旨在使領導層激勵措施與公司目標保持一致,從而有可能提高股東價值。完整協議載於該公司最新的美國證券交易委員會文件中的附錄10.1。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息